Press Release **For Immediate Release**

Glenmark Generics to launch Cyclobenzaprine Hydrochloride tablets in the US

- Glenmark will launch this product in partnership with InvaGen Pharmaceuticals, USA

July 30, 2010: Glenmark Generics Inc., USA (GGI), the United States subsidiary of Glenmark Generics Limited (GGL) has commenced marketing and distribution of Cyclobenzaprine Hydrochloride tablets in the U.S. market.

Cyclobenzaprine Hydrochloride tablets are the generic version of Flexeril® tablets of McNeil Pediatrics and are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Overall generic market sales for the product are approximately USD 36 million for the 12 month period ending March 2010, according to IMS Health Data.

The Abbreviated New Drug Application (ANDA) for Cyclobenzaprine Hydrochloride tablets was approved through Glenmark's longstanding partnership with InvaGen Pharmaceuticals Inc. (InvaGen). The Company will exclusively market and distribute the product while InvaGen will be responsible for their manufacture and supply. All profits on Cyclobenzaprine Hydrochloride tablets' sale in the U.S. will be shared between Glenmark and InvaGen.

In 2005, Glenmark and InvaGen entered into a collaboration agreement for the joint development, filing and marketing of several generic pharmaceutical products for the U.S. market. The product list included a mixture of off-patent and patent-protected molecules.

Glenmark's current portfolio consists of 58 products authorized for distribution in the U.S. marketplace. The Company has over 50 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.

About Glenmark Generics limited.
Glenmark Generics Limited (GGL) is a subsidiary of Glenmark Pharmaceuticals Limited (Glenmark) and aims to be a global integrated Generic and API leader.

GGL has an established presence in North America, a developing EU presence and Argentina

and maintains marketing front-ends in these countries. It primarily sells its FDF products in the United States ("US") and the European Union ("EU"), as well as its oncology FDF products in South America. The Company supplies APIs to customers in approximately 63 countries, including the US, various countries in the EU, South America and India.

Disclaimer

"Glenmark Generics Limited ("Company") is proposing, subject to market conditions and other considerations, a public issue of its equity shares and has filed a Draft Red Herring Prospectus with SEBI. The Draft Red Herring Prospectus is available on the website of SEBI at www.sebi.gov.in and the respective websites of the BRLMs at www.enam.com and www.kmcc.co.in.

Investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, see the section titled "Risk Factors" of the aforementioned Draft Red Herring Prospectus."

This press release is not an offer of securities for sale in the United States or elsewhere. The shares of Glenmark Generics Limited are not being registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States unless registered under the Securities Act or pursuant to an exemption from such registration. There will be no public offering of the shares in the United States.

NOT FOR PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA

#####

For further information, please contact:

Jason D'Souza

Glenmark, Mumbai, India

Tel: [+91 22] 40189919

Email : connect@glenmark-generics.com